October 21, 2017 7:38 AM ET

Biotechnology

Company Overview of Editas Medicine, Inc.

Key Executives for Editas Medicine, Inc.

NameBoard RelationshipsTitleAge
Katrine S. Bosley 36 RelationshipsChief Executive Officer, President and Director49
George M. Church Ph.D.237 RelationshipsCo-Founder and Scientific Advisory Board Member63
Jennifer A. Doudna Ph.D.41 RelationshipsCo-Founder--
J. Keith Joung M.D., Ph.D.33 RelationshipsCo-Founder and Scientific Advisory Board Member--
David R. Liu Ph.D.48 RelationshipsCo-Founder and Scientific Advisory Board Member--
View More Key Executives

Editas Medicine, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Katrine S. Bosley 36 RelationshipsEditas Medicine, Inc.49
Feng Zhang Ph.D. 105 RelationshipsEditas Medicine, Inc.--
George M. Church Ph.D. 237 RelationshipsEditas Medicine, Inc.63
J. Keith Joung M.D., Ph.D. 33 RelationshipsEditas Medicine, Inc.--
David R. Liu Ph.D. 48 RelationshipsEditas Medicine, Inc.--
View All Board Members

Editas Medicine, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Andrew Hirsch27 Relationships3 Executives
Compensation Committee Ph.D., J.D.John D. Mendlein83 Relationships3 Executives
Nominating Committee Ph.D., J.D.John D. Mendlein83 Relationships3 Executives
Corporate Governance Committee Ph.D., J.D.John D. Mendlein83 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$450.0K
450.0K
388.0K
Bonus
Not meaningful
Total Short Term Compensation$450.0K
450.0K
483.6K
Total Value of Options
17.8M
Compensation as of Fiscal Year
Editas Medicine, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Verseon Corporation Appoints Robert W. Karr as Non-Executive Class II Director
October 20, 2017 6:00 AM ET
Neurocrine Biosciences, Inc. Announces Management Changes
October 19, 2017 9:26 PM ET
AveXis, Inc. Announces Management Changes
October 19, 2017 8:58 PM ET
Peregrine Pharmaceuticals, Inc. and Avid Bioservices, Inc. Appoint Mark R. Bamforth as an Independent Member of the Board of Directors
October 19, 2017 12:05 PM ET
Cellect Biotechnology Ltd. Announces Executive Changes
October 19, 2017 11:05 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Editas Medicine, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.